Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05111626
Title Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Amgen
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin

Bemarituzumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST